Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7503 Following Multiple Ascending Dose Administration to Patients With Suspected Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)

NCT05864391 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05864391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05864391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7503 Following Multiple Ascending Dose Administration to Patients With Suspected Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Terminated
Start date
March 31, 2023
Completion date
March 20, 2024
Enrollment
40 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

steatohepatitis